Performance of different fetal growth charts in prediction of large-for-gestational age and associated neonatal morbidity in multiethnic obese population.

OBJECTIVES: To examine the performance of different fetal growth charts in the prediction of large-for-gestational age (LGA) and associated neonatal morbidity at term in a multiethnic, obese population. METHODS: This was a retrospective cohort study of 253 non-anomalous, singleton, term pregnancies that underwent serial third-trimester ultrasound scans due to maternal body mass index ≥ 35 kg/m2 . We compared the performance of the Hadlock, Gestation Related Optimal Weight (GROW), INTERGROWTH-21st (IG-21), World Health Organization (WHO) and Fetal Medicine Foundation (FMF) fetal growth reference charts in the prediction of LGA at birth, defined as birth weight > 90th percentile, and neonatal morbidity, defined as a composite of neonatal intensive care unit admission or 5-min Apgar score < 7. RESULTS: In the study population, 53 (20.9%) infants were born LGA, 27 (10.7%) experienced neonatal morbidity and nine (3.6%) were LGA with associated neonatal morbidity. The Hadlock and GROW charts showed similar performance in predicting LGA, with sensitivity of 66.0% for both and specificity of 82.5% and 83.5%, respectively. The positive likelihood ratios (LR+) were 3.77 (95% CI, 2.64-5.40) and 4.00 (95% CI, 2.77-5.78), respectively. The IG-21, WHO and FMF charts performed similarly and had higher sensitivity of about 85%, with specificity between 66% and 72%. LR+ was 2.74 (95% CI, 2.16-3.47), 2.50 (95% CI, 2.00-3.12) and 3.03 (95% CI, 2.36-3.89), respectively. All charts had high sensitivity for predicting neonatal morbidity associated with LGA, with LR+ ranging between 2.35 and 3.61. CONCLUSIONS: In our multiethnic, obese population, all fetal growth charts performed well in predicting LGA and associated neonatal morbidity. However, the choice of fetal reference chart is likely to affect intervention rates. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

Cervical cancer still presents symptomatically 20 years after the introduction of a structured national screening programme.

OBJECTIVE: To investigate the pattern of presentation of cervical cancer and to identify the characteristics of women who present symptomatically with cervical cancer. METHODS: A retrospective study of all cervical cancer cases diagnosed over a 4-year period. Details of mode of presentation, stage at diagnosis and cytological/gynaecological history were collated. RESULTS: In total, 148 cases were identified with a median age of 46 years (range, 20-91 years). In this population, 112 (75.7%) women were within the screening age range. Forty-eight (33.6%) were asymptomatic at diagnosis and presented through the colposcopy clinic. All asymptomatic women (100%) had stage I disease at diagnosis, compared with 37.2% of the symptomatic group (P < 0.001). Postmenopausal bleeding was the most common presenting symptom (33%), followed by postcoital bleeding (14.2%), intermenstrual bleeding (12.2%) and increased vaginal discharge (3.4%). The majority of symptomatic women presented through colposcopy, gynaecological oncology or gynaecology clinics (87.6%); however, 6.5% presented through the emergency department. Women who presented symptomatically were significantly older than asymptomatic women (54.9 versus 38.1 years, P < 0.001). Women at risk of social isolation (non-English speakers, alcohol abusers, heavy smokers, receiving treatment for psychiatric disease) were more likely to present with symptoms, through the emergency department and with advanced disease at diagnosis (stage II+) (P < 0.001). CONCLUSIONS: A review of local cervical cancer cases can highlight areas of weakness in a screening programme and can identify populations who are at risk in presenting symptomatically with advanced disease.